The New Drug Reimbursement Game: A Regulator's Guide to Playing and Winning (Hardback)
  • The New Drug Reimbursement Game: A Regulator's Guide to Playing and Winning (Hardback)
zoom

The New Drug Reimbursement Game: A Regulator's Guide to Playing and Winning (Hardback)

(author)
£53.99
Hardback 248 Pages / Published: 27/10/2014
  • We can order this

Usually despatched within 3 weeks

  • This item has been added to your basket

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population's future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure.

Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society's welfare. The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm's production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price.

The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.

Publisher: Springer International Publishing AG
ISBN: 9783319089027
Number of pages: 248
Weight: 5207 g
Dimensions: 235 x 155 x 20 mm
Edition: 2015 ed.


MEDIA REVIEWS

"I like this book ... and would recommend it to anyone who wishes to understand the negotiations between health-care payers and biopharmaceutical companies. ... Pekarsky provides useful overviews of the many academic fields that contribute to debates on the appropriate price to pay for new drugs ... ." (Christopher J. McCabe, Applied Health Economics and Health Policy, October, 2015)

You may also be interested in...

Pass the PSA
Added to basket
£32.99
Paperback
Recovering with T3
Added to basket
£19.45
Paperback
Aromatherapy Lexicon
Added to basket
£4.99
Paperback
Psychiatric Drugs Explained
Added to basket
Medical Dosage Calculations For Dummies
Added to basket
An Introduction to Drug Synthesis
Added to basket
The Dmso Handbook for Doctors
Added to basket
The Fragrant Mind
Added to basket

Reviews

Please sign in to write a review

Your review has been submitted successfully.